EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Immune-infiltrated kidney organoid-on-chip model for assessing T cell bispecific antibodies

Katharina T Kroll, Mariana M Mata, Kimberly A Homan, Virginie Micallef, Alejandro Carpy, Ken Hiratsuka, Ryuji Morizane, Annie Moisan, Marcel Gubler, Antje-Christine Walz, Estelle Marrer-Berger, Jennifer A Lewis iD

Proceedings of the National Academy of Sciences · 29.08.2023 · 120 (35)

DOI: 10.1073/pnas.2305322120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 21.08.2023. Verfasst von Katharina T Kroll und 11 weiteren Autor:innen. Beteiligte Einrichtung: Harvard University, School of Engineering and Applied Sciences, Cambridge, MA 02138. Hauptthemen laut MEDLINE: Antibodies, Bispecific. Die Arbeit wurde bisher 81-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, Roche Pharma Research & Early Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T cell bispecific antibodies (TCBs) are the focus of intense development for cancer immunotherapy. Recently, peptide-MHC (major histocompatibility complex)-targeted TCBs have emerged as a new class of biotherapeutics with improved specificity. These TCBs simultaneously bind to target peptides presented by the polymorphic, species-specific MHC encoded by the human leukocyte antigen (HLA) allele present on target cells and to the CD3 coreceptor expressed by human T lymphocytes. Unfortunately, traditional models for assessing their effects on human tissues often lack predictive capability, particularly for “on-target, off-tumor” interactions. Here, we report an immune-infiltrated, kidney organoid-on-chip model in which peripheral blood mononuclear cells (PBMCs) along with nontargeting (control) or targeting TCB-based tool compounds are circulated under flow. The target consists of the RMF peptide derived from the intracellular tumor antigen Wilms’ tumor 1 (WT1) presented on HLA-A2 via a bivalent T cell receptor-like binding domain. Using our model, we measured TCB-mediated CD8 + T cell activation and killing of RMF-HLA-A2-presenting cells in the presence of PBMCs and multiple tool compounds. DP47, a non-pMHC-targeting TCB that only binds to CD3 (negative control), does not promote T cell activation and killing. Conversely, the nonspecific ESK1-like TCB (positive control) promotes CD8 + T cell expansion accompanied by dose-dependent T cell–mediated killing of multiple cell types, while WT1-TCB* recognizing the RMF-HLA-A2 complex with high specificity, leads solely to selective killing of WT1-expressing cells within kidney organoids under flow. Our 3D kidney organoid model offers a platform for preclinical testing of cancer immunotherapies and investigating tissue-immune system interactions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificHumansHLA-A2 AntigenLeukocytes, MononuclearKidneyOrganoids

Stichwörter der Autor:innen

T cell bispecific antibodiesimmuno-oncologykidney organoidsorgan-on-chip

Substanzen

Antibodies, BispecificHLA-A2 Antigen

Autor:innen und Institutionen

  • Harvard University, School of Engineering and Applied Sciences, Cambridge, MA 02138.
  • Wyss Institute for Biologically Inspired Engineering, Boston, MA 02115.
  • Complex in vitro Systems, Safety Assessment, Genentech Inc., South San Francisco, CA 94080.
  • Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel CH-4070, Switzerland.
  • Roche Pharma Research and Early Development, Roche Innovation Center Munich, Munich DE-82377, Germany.
  • Department of Medicine, Harvard Medical School, Boston, MA 02115.

ORCID-Profile: Jennifer A Lewis

Förderung

  • NIDDK NIH HHS
  • NCATS NIH HHS
  • Roche Pharma Research & Early Development
  • HHS | NIH | National Center for Advancing Translational Sciences
  • International Foundation of Ethical Research

Zitieren

APA

Kroll, K. T., Mata, M. M., Homan, K. A., Micallef, V., Carpy, A., Hiratsuka, K., Morizane, R., Moisan, A., Gubler, M., Walz, A. C., Marrer-Berger, E., & Lewis, J. A. (2023). Immune-infiltrated kidney organoid-on-chip model for assessing T cell bispecific antibodies. Proceedings of the National Academy of Sciences, 120(35). https://doi.org/10.1073/pnas.2305322120

Vancouver

Kroll KT, Mata MM, Homan KA, Micallef V, Carpy A, Hiratsuka K, et al. Immune-infiltrated kidney organoid-on-chip model for assessing T cell bispecific antibodies. Proceedings of the National Academy of Sciences. 2023;120(35). doi:10.1073/pnas.2305322120

BibTeX
@article{Kroll2023,
  author = {Kroll, Katharina T and Mata, Mariana M and Homan, Kimberly A and Micallef, Virginie and Carpy, Alejandro and Hiratsuka, Ken and Morizane, Ryuji and Moisan, Annie and Gubler, Marcel and Walz, Antje-Christine and Marrer-Berger, Estelle and Lewis, Jennifer A},
  title = {Immune-infiltrated kidney organoid-on-chip model for assessing T cell bispecific antibodies},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2023},
  volume = {120},
  number = {35},
  doi = {10.1073/pnas.2305322120}
}
Kostenlos starten →